Background: Platinum-based chemotherapy with cetuximab is a standard treatment for recurrent and/or metastatic squamous cell carcinoma of the head and neck. However, the efficacy and the safety of cetuximab-containing chemotherapy subsequent to immune checkpoint inhibitor use have not been well investigated. Herein, we report a case of remarkable response to combination chemotherapy with cetuximab for a patient with recurrent tongue cancer refractory to immune checkpoint inhibitors. Case: A 52-year-old man with unresectable locoregional after definitive surgery for tongue cancer was treated with the combination of anti-programmed death ligand 1 (PD-L1) antibody and anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) antibody as a clinical trial. Despite treatment, disease progression was observed. He then received combination chemotherapy with cisplatin, 5FU and cetuximab. During the first cycle, he complained of dysphagia from day 9 and a CT scan on day 14 revealed an oral-cutaneous fistula due to rapid tumor shrinkage. Discussion/Conclusion: The overall response rate of platinum-based chemotherapy with cetuximab as first-line treatment was 35.6% in the EXTREME trial. In phase II trials of combination chemotherapy with cetuximab, median time to response was around 45 days. Mechanisms of the anti-tumor effect of cetuximab are inhibition of signal transduction of the EGFR pathway, and stimulation of ADCC and effector cell activity. On the basis, his clinical course suggests that combination chemotherapy with cetuximab subsequent to immune checkpoint inhibitors might have augmented the anti-tumor immune response, resulting in remarkable tumor regression. Background: Treatments options for metastatic breast cancer (MBC) have become more efficacious and numerous. Eribulin is an active agent for MBC treatment, but the effective usage of this drug is still unclear. Although the usage of eribulin for MBC in Europe is limited to patients who exposed to minimum of two previous chemotherapy regimens including anthracyclines and taxanes in the adjuvant or metastatic setting, there is no such strict limitation in Japan. The purpose of this retrospective study is to evaluate effective usage of erubulin in pretreated metastatic breast cancer patients in daily practice. Patients & methods: Chart review was done for the patients who underwent chemotherapy, which include at least paclitaxel or eribulin for metastatic breast cancer between October 2012 and April 2016 in our single institute. One hundred and fifty patients were included in our cohort. The primary efficacy measure assessed overall survival (OS).
Background: Treatments options for metastatic breast cancer (MBC) have become more efficacious and numerous. Eribulin is an active agent for MBC treatment, but the effective usage of this drug is still unclear. Although the usage of eribulin for MBC in Europe is limited to patients who exposed to minimum of two previous chemotherapy regimens including anthracyclines and taxanes in the adjuvant or metastatic setting, there is no such strict limitation in Japan. The purpose of this retrospective study is to evaluate effective usage of erubulin in pretreated metastatic breast cancer patients in daily practice. Patients & methods: Chart review was done for the patients who underwent chemotherapy, which include at least paclitaxel or eribulin for metastatic breast cancer between October 2012 and April 2016 in our single institute. One hundred and fifty patients were included in our cohort. The primary efficacy measure assessed overall survival (OS). Result: Among human epidermal growth factor receptor 2 (HER2) negative patients, 51 received eribulin (eribulin group) and 66 received conventional chemotherapy excluding erubulin (non-eribulin group). The median OS from MBC diagnosis in the eribulin group was 39.0 months compared with 22.7 months in the non-eribulin group [hazard ratio (HR): 0.46, 95%CI 0.29-0.73; p ¼ 0.001]. Eribulin seemed to have significant survival benefit in patients with lung metastasis, but not in patients without lung metastasis in our cohort. Same trend was recognized with liver metastasis, or bone metastasis. Conclusion: Eribulin therapy may have a survival benefit in Japanese women with HER2 negative MBC. And may have benefit in MBC patients with lung, liver or bone metastasis. Results: In triple negative breast cancer patients (n ¼ 173) after NAC (n ¼ 44), 34% of them achieved pathological complete response (n ¼ 15) and 66% had residual tumor (n ¼ 29). We identified five patients with residual tumor after NAC, from January 2016 to February 2017, who received adjuvant capecitabine (2500mg/m 2 , oral, day1-14, every three weeks, eight cycles). They were all Japanese women, median age was thirtyeight (ranged from thirty to fifty-eight), ECOG PS 0 to1, stage IA to IIB. Four patients received dose dense regimen of doxorubicin (60mg/m 2 ) and cyclophosphamide (600mg/m 2 ) for four cycles every two weeks (ddAC) followed by weekly paclitaxel (80mg/m 2 ) for twelve weeks as NAC. One patient with BRCA mutation received ddAC followed by carboplatin (AUC6, day1) and paclitaxel (80mg/m 2 , day1,8,15) every three weeks for four cycles. Two patients underwent partial mastectomy and three patients had total mastectomy. There was one episode of grade 3 neutropenia due to capecitabine, which resulted in 1-step dose reduction. Two patients had grade 2 hand-foot syndrome (HFS) and recovered after 1-step dose reduction. Two patients tolerated grade 1 HFS by withdrawal and supportive therapy. All patients could complete eight cycles of adjuvant capecitabine. No patient experienced febrile neutropenia. Conclusions: For triple negative breast cancer patients with residual tumor after NAC, toxicities of adjuvant capecitabine were feasible. Background: Earlier researches have determined breast cancer risk factors. Women with risk factors were encouraged for breast physical exam screening which is readily accessible. However, statistics about significant risk factors which caused positive breast physical exam results were unknown. The aim of this study is to know the association between breast cancer risk factors and breast physical exam lump findings in Indonesia. Methods: This study is a cross-sectional study in Tangerang suburban area on January 2017. Volunteering women were evaluated for several breast cancer risk factors. Their breast were evaluated by the oncology team for lump positivity. Baseline characteristics were presented using descriptive statistics. Analysis of association was done using chi square test and binary logistic regression test. Results: A total of 71 women, with median age 41 (16-59) year old and BMI 23.98 were enrolled to the study. Overall, 9.9% had family history of breast cancer; 2.8% had history of cancer; 19.7% had family history of cancer and 7.04% had ovarian cyst history. All of them never had breast cancer, exposed to radiation, nor drank alcohol. Moreover, 5.7% were pregnant after 30 years old; 8.9% have not had breast-feeding; 84.5% were menopausal; 81.7% had received hormonal pill and 17% had menarche under 12 years old. Family history of breast cancer, history of breast surgery, history of having lump in breast or axilla, breast pain, menopause, and history of ovarian cyst were associated with positive lump. After adjusted with several confounding, family history of breast cancer (OR 24.36), history of having mass in breast or axilla (OR 62.16) , and menopause status (OR 18.4) were the only risk factors statistically significant. Conclusion: Family history of breast cancer, history of having mass in breast or axilla, and menopause status were associated with lump findings in breast physical exam. 
